Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

COSTEM 2019 | How do we bridge to transplant in relapsed ALL?

Peihua Lu • 25 Oct 2019
COSTEM 2019
Acute Lymphoblastic Leukemia Leukemia CAR-T

Peihua Lu, MD, Lu Daopei hospital, Beijing, China, provides insight as to how we might bridge the gap to transplant in relapsed acute lymphoblastic leukemia (ALL) with CAR-T cell therapy. This interview took place at the 5th International Congress on Controversies in Stem Cell Transplantation and Cellular Therapies (COSTEM) 2019, held in Berlin, Germany.

More from Peihua Lu

1:15
AlloSCT outcomes in patients who achieve CR with CAR-T versus chemotherapy in T-ALL/LBL
Peihua Lu • 9 Dec 2023
0:53
Anti-CD7 CAR-T therapy for T-ALL/LBL
Peihua Lu • 9 Dec 2023
3:16
CD-7 targeted CAR-T therapy in heavily pretreated patients with AML: a Phase I trial
Peihua Lu • 9 Dec 2023
2:16
Evaluating the safety and efficacy of novel anti-CD7 universal CAR-T therapy in R/R T-ALL and T-LBL
Peihua Lu • 12 Dec 2022

Related Videos

1:51
Should MRD eradication be the goal when treating every patient with CLL?
Dima El-Sharkawi • 28 Apr 2024
1:40
The role of CPX-351 in the AML treatment landscape & insights into the AMLSG 30-18 trial
Felicitas Thol • 19 Apr 2024
3:21
Integrating genomics and MRD in transplant decision-making for patients with AML
Jurjen Versluis • 22 Apr 2024
4:19
Blinatumomab to achieve remission and consolidation with haploSCT for pediatric ALL
Alberto Olaya-Vargas • 15 Apr 2024
The content of VJHemOnc is intended for healthcare professionals